Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
With
Forest Laboratories
Despite it's high prevalence, little is known about the pharmacological treatment of depression following Traumatic Brain Injury (TBI). This is because of a lack of randomized controlled studies in the treatment of post-TBI depression. This study is designed to examine the safety and effectiveness of escitalopram in the treatment of post-TBI depression. It will also investigate metabolic changes and neural pathways associated with post-TBI depression and metabolic alterations after treatment through neuroimaging.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Closed head injury
Fulfill Diagnostic and Statistical Manual Diploma in Social Medicine (DSM) IV criteria "Major Depressive Disorder"
18 years of age or older
Able to provide informed consent
Stable medical history
You may not be if
History of Stroke, Encephalitis, Seizures, or any other pre-TBI neurological diseases
History of mental retardation
Alcohol or Substance dependence in the last 1 year
Inability to undergo MRI scan
Pregnancy
Current use of any psychotropic medications including any antidepressants, antipsychotics, anxiolytics, or sedative hypnotics
Poor response to escitalopram in the past
Acutely suicidal or requiring inpatient psychiatric hospitalization, as determined by the study psychiatrist
Good medication response to another antidepressant in the past
